Reduced short latency afferent inhibition in diffuse axonal injury patients with memory impairment
Reduced short latency afferent inhibition in diffuse axonal injury patients with memory impairment
复制标题
DOI：
10.1016/j.neulet.2006.07.005
复制
发表时间：
2006-09-25
影响因子：
2.5
通讯作者：
Kobayashi, Hidenori
中科院分区：
文献类型：
--
作者：
Fujiki, Minoru;Hikawa, Takarnitsu;Kobayashi, Hidenori
本研究采用短间期皮层内抑制（SICI）、皮层内易化（ICF）和短潜伏期传入抑制（SAI）技术，对16例弥漫性轴索损伤（DAI）伴记忆障碍患者的运动皮层兴奋性进行了评价，并与16例健康对照者进行了比较。与对照组相比，患者的SAI降低（92 +/- 12 vs 39 +/- 11%的测试大小; p < 0.0001，非配对t检验）。与对照组相比，DAI患者倾向于具有较高的静息运动阈值（RMT）和较不明显的SICI和ICF，但这些差异均不显著。单次口服剂量（3 mg）的多奈哌齐（一种常用于治疗阿尔茨海默病（AD）的乙酰胆碱酯酶抑制剂）改善了DAI患者的SAI，个体差异很大，范围从增加77-18%的测试大小。这些发现表明，测量SAI可能提供一种探测受损人脑中胆碱能网络完整性的方法。(c)2006爱思唯尔爱尔兰有限公司保留所有权利。
The present study used short interval intracortical inhibition (SICI), intracortical facilitation (ICF), and short latency afferent inhibition (SAI) to evaluate motor cortex excitability in 16 diffuse axonal injury (DAI) patients with memory impairment and compared the data with those of 16 healthy controls. SAI was reduced in patients compared with controls (92 +/- 12 versus 39 +/- 11% of the test size; p < 0.0001, unpaired t-test). DAI patients tended to have a high resting motor threshold (RMT) and less pronounced SICI and ICF than controls, but these differences were not significant. A single oral dose (3 mg) of donepezil, an acetylcholinesterase inhibitor that is commonly used to treat Alzheimer's disease (AD), improved SAI in DAI patients with wide individual variations that ranged from an increase of 77-18% of test size. These findings suggest that measuring SAI may provide a means of probing the integrity of cholinergic networks in an injured human brain. (c) 2006 Elsevier Ireland Ltd. All rights reserved.